Fintel reports that on January 7, 2026, Piper Sandler initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Overweight recommendation.
Analyst Price Forecast Suggests 162.10% Upside
As of December 21, 2025, the average one-year price target for ORIC Pharmaceuticals is $21.34/share. The forecasts range from a low of $15.15 to a high of $26.25. The average price target represents an increase of 162.10% from its latest reported closing price of $8.14 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for ORIC Pharmaceuticals is 44MM. The projected annual non-GAAP EPS is -2.20.
What is the Fund Sentiment?
There are 320 funds or institutions reporting positions in ORIC Pharmaceuticals. This is an decrease of 13 owner(s) or 3.90% in the last quarter. Average portfolio weight of all funds dedicated to ORIC is 0.43%, an increase of 1.32%. Total shares owned by institutions increased in the last three months by 12.39% to 116,212K shares. 
The put/call ratio of ORIC is 0.14, indicating a bullish outlook.
What are Other Shareholders Doing?
Nextech Invest holds 7,163K shares representing 7.35% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 6,728K shares representing 6.91% ownership of the company. In its prior filing, the firm reported owning 1,618K shares , representing an increase of 75.95%. The firm increased its portfolio allocation in ORIC by 298.53% over the last quarter.
VR Adviser holds 6,597K shares representing 6.77% ownership of the company. No change in the last quarter.
Viking Global Investors holds 6,573K shares representing 6.75% ownership of the company. No change in the last quarter.
Pfizer holds 5,376K shares representing 5.52% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
